Gene and Cell Therapy · us
Directly Correcting the Sickle Cell Disease Mutation: UCLA Unveils a Clinical-Scale CRISPR Manufacturing Process
Four full-scale manufacturing batches met quality requirements, and the process has also produced cells for two early-stage trial participants. As gene correction moves toward treatment, the next test is whether the cells can sustain blood cell production in the human body over the long term and deliver lasting clinical benefits.
Correcting a disease-causing mutation and reliably manufacturing the corrected cells into a product for patient use are two distinct hurdles. The sickle cell disease research announced by UCLA focuses on the latter: the team established a clinical-scale process for editing blood stem cells, with all four full-scale manufacturing batches meeting quality requirements, and has prepared cell products for two participants in an ongoing Phase 1 trial. These advances, however, do not yet establish how patients will fare after treatment.
The investigational therapy, called CRISPR_SCD001, uses patients’ own hematopoietic stem cells and combines CRISPR-Cas9 with a single-stranded DNA repair template to directly correct the sickle cell disease mutation in the HBB gene. The aim is for the reinfused cells to establish blood cell production in the bone marrow and continuously generate red blood cells containing healthier hemoglobin, reducing the harm caused by the disease.
The paper, published in *Molecular Therapy*, provides concrete data on the reproducibility of the manufacturing process. Across large-scale batches, CD34-positive cell purity averaged 89%±5%, and viability was 84%±6%; the proportion of corrected HBB alleles averaged 22%±4%. This correction rate is calculated by gene copy and cannot be interpreted directly as the same proportion of cells having been fully restored to normal.
Editing does not always result in the intended precise repair. The study also reported sequence disruption in an average of 51%±6% of alleles. Assessing this technology therefore requires examining other editing outcomes and their effects, alongside the proportion of successful corrections. In red blood cell differentiation cultures, the proportion of sickle hemoglobin fell from 89% to 22%±6%, and adult and fetal hemoglobin were produced. This provides supporting evidence of function, but remains a laboratory finding.
Animal studies tested whether these cells could persist after transplantation. The researchers observed cell engraftment in immunodeficient mice, with the gene correction rate remaining at approximately 20%, close to the level in the infused cells; blinded histopathological assessment found no apparent treatment-related toxicity or lesions. These findings support proceeding to human studies, but cannot replace long-term safety follow-up in humans.
Information from the funding agency, the California Institute for Regenerative Medicine, links the same manufacturing paper to the CRISPR_SCD001 clinical program. The trial plans to enroll up to nine people at UCSF and UCLA, initially treating adults in stages and assessing safety sequentially, before considering the inclusion of adolescents based on safety and efficacy results. Participants must still undergo chemotherapy before receiving their own corrected cells, so the burden of the overall treatment course must also be considered.
The value of these newly released data lies in turning a strategy for directly correcting a disease-causing mutation into a reproducibly manufactured cell product that can be evaluated clinically. The crucial evidence ahead will concern whether blood cell production can be sustained in the human body, whether disease complications decrease, and how risks related to editing and transplantation emerge over time. The manufacturing and preclinical results released so far are not sufficient to claim that the therapy has been proven effective.